[EFFECTIVENESS OF HOCHUEKKITO (JAPANESE HERBAL MEDICINE) FOR GENERAL FATIGUE AFTER INTRODUCTION OF ENZALUTAMIDE IN THREE CASES OF CASTRATION-RESISTANT PROSTATE CANCER].

Q4 Medicine Japanese Journal of Urology Pub Date : 2019-01-01 DOI:10.5980/jpnjurol.110.86
Tomonori Minagawa, Takahisa Domen, Toshiro Suzuki, Manabu Ueno, Takashi Nagai, Teruyuki Ogawa, Hideo Kiyokawa, Osamu Ishizuka
{"title":"[EFFECTIVENESS OF HOCHUEKKITO (JAPANESE HERBAL MEDICINE) FOR GENERAL FATIGUE AFTER INTRODUCTION OF ENZALUTAMIDE IN THREE CASES OF CASTRATION-RESISTANT PROSTATE CANCER].","authors":"Tomonori Minagawa,&nbsp;Takahisa Domen,&nbsp;Toshiro Suzuki,&nbsp;Manabu Ueno,&nbsp;Takashi Nagai,&nbsp;Teruyuki Ogawa,&nbsp;Hideo Kiyokawa,&nbsp;Osamu Ishizuka","doi":"10.5980/jpnjurol.110.86","DOIUrl":null,"url":null,"abstract":"<p><p>(Purpose) Enzalutamide is one of the therapeutic options for castration-resistant prostate cancer (CRPC). However, general fatigue is frequently observed in patients after introduction of enzalutamide. Here, we used the Cancer Fatigue Scale (CFS) to monitor general fatigue after introduction of enzalutamide, and administered the Japanese herbal medicine (Kampo) drug, Hochuekkito, for management of general fatigue. (Materials and methods) Three patients with CRPC were enrolled in this retrospective observational study. The patients were all male, 72, 69, and 88 years old, respectively, and had received previous hormone therapy for CRPC. They complained of general fatigue 2-5 weeks after introduction of enzalutamide. The CFS was divided into three subcategories: physical fatigue, affective fatigue, and cognitive fatigue. Hochuekkito was prescribed for management of general fatigue. Moreover, 31 previous CRPC cases treated in our hospital were divided into a general fatigue group and a non-general fatigue group. The period of enzalutamide prescription was compared among the previous groups and the present three cases to determine the usefulness of Hochuekkito. (Results) In this series, CFS was useful to monitor general fatigue after introduction of enzalutamide. General fatigue after introduction of enzalutamide mainly consisted of physical fatigue, and improved in two of the three cases included in this study. However, enzalutamide was discontinued in one patient due to general fatigue. Fourteen of our 31 previous CRPC cases developed general fatigue after introduction of enzalutamide. The mean periods of enzalutamide prescription were 265.6, 173.2, and 193.0 days in the non-general fatigue, general fatigue, and the present three cases, respectively. The differences among the groups were not significant. (Conclusions) The CFS is useful to monitor general fatigue, including its subcategories, after introduction of enzalutamide in patients with CRPC. The Kampo medicine Hochuekkito may be useful for management of general fatigue in such cases.</p>","PeriodicalId":38850,"journal":{"name":"Japanese Journal of Urology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5980/jpnjurol.110.86","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 5

Abstract

(Purpose) Enzalutamide is one of the therapeutic options for castration-resistant prostate cancer (CRPC). However, general fatigue is frequently observed in patients after introduction of enzalutamide. Here, we used the Cancer Fatigue Scale (CFS) to monitor general fatigue after introduction of enzalutamide, and administered the Japanese herbal medicine (Kampo) drug, Hochuekkito, for management of general fatigue. (Materials and methods) Three patients with CRPC were enrolled in this retrospective observational study. The patients were all male, 72, 69, and 88 years old, respectively, and had received previous hormone therapy for CRPC. They complained of general fatigue 2-5 weeks after introduction of enzalutamide. The CFS was divided into three subcategories: physical fatigue, affective fatigue, and cognitive fatigue. Hochuekkito was prescribed for management of general fatigue. Moreover, 31 previous CRPC cases treated in our hospital were divided into a general fatigue group and a non-general fatigue group. The period of enzalutamide prescription was compared among the previous groups and the present three cases to determine the usefulness of Hochuekkito. (Results) In this series, CFS was useful to monitor general fatigue after introduction of enzalutamide. General fatigue after introduction of enzalutamide mainly consisted of physical fatigue, and improved in two of the three cases included in this study. However, enzalutamide was discontinued in one patient due to general fatigue. Fourteen of our 31 previous CRPC cases developed general fatigue after introduction of enzalutamide. The mean periods of enzalutamide prescription were 265.6, 173.2, and 193.0 days in the non-general fatigue, general fatigue, and the present three cases, respectively. The differences among the groups were not significant. (Conclusions) The CFS is useful to monitor general fatigue, including its subcategories, after introduction of enzalutamide in patients with CRPC. The Kampo medicine Hochuekkito may be useful for management of general fatigue in such cases.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[日本中草药恩杂鲁胺治疗去势抵抗性前列腺癌后全身乏力3例疗效观察]。
(目的)恩杂鲁胺是去势抵抗性前列腺癌(CRPC)的治疗选择之一。然而,在引入恩杂鲁胺后,患者经常观察到全身疲劳。本研究采用癌症疲劳量表(Cancer Fatigue Scale, CFS)监测恩杂鲁胺(enzalutamide)引入后的全身疲劳,并使用日本中草药(Kampo)药物Hochuekkito治疗全身疲劳。(材料与方法)本研究纳入3例CRPC患者。患者均为男性,年龄分别为72岁、69岁和88岁,既往接受过CRPC激素治疗。患者在使用恩杂鲁胺2-5周后出现全身疲劳。慢性疲劳综合症分为三个子类:躯体疲劳、情感性疲劳和认知疲劳。护护服是用来治疗全身疲劳的。将我院收治的31例CRPC患者分为一般疲劳组和非一般疲劳组。比较前两组患者和本例患者的恩杂鲁胺处方时间,以确定本品的有效性。(结果)CFS可用于监测恩杂鲁胺引入后的全身疲劳。引入恩杂鲁胺后的全身疲劳主要为躯体疲劳,本研究3例中有2例得到改善。然而,一名患者因全身疲劳停用了enzalutamide。我们先前的31例CRPC病例中有14例在引入恩杂鲁胺后出现全身疲劳。非全局性疲劳、全局性疲劳和本例患者的平均用药时间分别为265.6、173.2和193.0 d。各组间差异不显著。(结论)CFS可用于监测CRPC患者引入恩杂鲁胺后的全身疲劳及其亚类别。在这种情况下,汉布药Hochuekkito可能对管理全身疲劳有用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Japanese Journal of Urology
Japanese Journal of Urology Medicine-Urology
CiteScore
0.20
自引率
0.00%
发文量
0
期刊最新文献
[PROSTATE-SPECIFIC ANTIGEN LEVEL AT 6 MONTHS AFTER RADICAL PROSTATECTOMY ENABLES STRATIFICATION OF FOLLOW-UP PERIODS IN THE CANCER REGIONAL ALLIANCES CRITICAL PATH]. [STUDY OF URINATION TREATMENT AFTER BCG INTRAVESICAL INSTILLATION THERAPY]. [OVERALL SURVIVAL EVALUATION OF PROSTATE CANCER PATIENTS TREATED WITH ANDROGEN DEPRIVATION THERAPY BY ESTIMATING FLUCTUANT PATTERNS OF METABOLIC FACTOR SERUM LEVELS]. [A CASE OF PRIMARY MUCOSA-ASSOCIATED LYMPHOID TISSUE (MALT) LYMPHOMA OF THE URINARY BLADDER]. [IPSILATERAL SYNCHRONOUS FUMARATE HYDRATASE-DEFICIENT RENAL CELL CARCINOMA AND MULTILOCULAR CYSTIC RENAL NEOPLASM OF LOW MALIGNANT POTENTIAL: A CASE REPORT AND LITERATURE REVIEW].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1